Pacira BioSciences, Inc.
NASDAQPacira BioSciences is entering the back half of 2026 with a notable tension: short sellers hold one of the largest positions in the pharmaceutical sector, yet the stock has quietly gained ground and analysts are nudging targets higher after yesterday's earnings release. The short position deserves the opening frame here. At 16% of the free float, short interest is substantial by…
Snapshot as of 6 Aug 2026
Pacira BioSciences is entering the back half of 2026 with a notable tension: short sellers hold one of the largest positions in the pharmaceutical sector, yet the stock has quietly gained ground and analysts are…
Pacira BioSciences heads into its July 31 earnings report with a notable gap opening between a still-heavy short position and a stock that has quietly put together its best month in some time. The short interest story…
Pacira BioSciences enters the final stretch before its June 9 earnings with a notable split: the stock has bounced sharply while shorts have barely budged. The price action this week is the sharpest divergence in…
PCRX heads into its May 1 earnings print with a notable divergence: short sellers are retreating while company insiders are cashing out. The short-side picture has shifted meaningfully heading into the release. Short…
Pacira BioSciences heads into its Q1 2026 earnings release — due after the close today — with two colliding stories: a meaningful short-covering wave over the past week, and an active proxy battle with a dissident…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PCRX — free to start on ORTEX.
Sign up for free →Open PCRX on ORTEX